Nicole Sweeny Sells 1,489 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Nicole Sweeny sold 1,489 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $26.78, for a total value of $39,875.42. Following the completion of the sale, the insider owned 59,291 shares in the company, valued at approximately $1,587,812.98. The trade was a 2.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nicole Sweeny also recently made the following trade(s):

• On Friday, May 22nd, Nicole Sweeny sold 1,861 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $26.78, for a total value of $49,837.58.
• On Friday, April 17th, Nicole Sweeny sold 1,862 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $20.22, for a total value of $37,649.64.

KalVista Pharmaceuticals Stock Down 0.1%

Shares of NASDAQ KALV opened at $26.77 on Friday. The stock has a market cap of $1.43 billion, a P/E ratio of -7.74 and a beta of -0.12. The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a 12-month low of $9.83 and a 12-month high of $26.85. The business’s fifty day simple moving average is $22.14 and its 200-day simple moving average is $17.76.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The company had revenue of $40.86 million for the quarter, compared to analysts’ expectations of $39.03 million. As a group, equities analysts predict that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current fiscal year.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KALV. Parallel Advisors LLC raised its holdings in KalVista Pharmaceuticals by 45.8% during the first quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 589 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 1,292 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in KalVista Pharmaceuticals during the third quarter worth approximately $55,000. Royal Bank of Canada raised its holdings in KalVista Pharmaceuticals by 137.0% during the first quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock worth $59,000 after purchasing an additional 1,686 shares in the last quarter. Finally, Truvestments Capital LLC raised its holdings in KalVista Pharmaceuticals by 253.8% during the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after purchasing an additional 3,360 shares in the last quarter.

Analysts Set New Price Targets

KALV has been the topic of several analyst reports. Leerink Partners cut shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Needham & Company LLC cut shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 30th. Stifel Nicolaus raised their target price on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, March 26th. JonesTrading cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 30th. Finally, HC Wainwright cut KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $37.00 to $27.00 in a research note on Friday, May 1st. Three equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $30.60.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.